Patient characteristics
Characteristic . | No. of patients (N = 316) . | % . |
---|---|---|
Median age, y | 66 (33-90) | |
Median LDH, U/L (range; n = 243) | 338 (136-1432) | — |
Median β2-microglobulin, mg/L (range; n = 294) | 2.2 (0.36-14.3) | — |
Sex | ||
Male | 177 | 56.0 |
Female | 139 | 44.0 |
Binet stage (n = 289) | ||
A | 242 | 83.7 |
B-C | 47 | 16.3 |
BM pattern (n = 149) | ||
Not diffuse | 125 | 83.9 |
Diffuse | 24 | 16.1 |
IGHV mutational status (n = 268) | ||
Mutated (≥ 2%) | 184 | 68.7 |
Unmutated (< 2%) | 84 | 31.3 |
CD38 (n = 308) | ||
CD38− (< 30%) | 233 | 75.6 |
CD38+ (≥ 30%) | 75 | 24.4 |
ZAP-70 (n = 264) | ||
ZAP-70− (< 20%) | 160 | 60.6 |
ZAP-70+ (≥ 20%) | 104 | 39.4 |
CD49d (n = 164) | ||
CD49d− (< 30%) | 106 | 64.6 |
CD49d+ (≥ 30%) | 58 | 35.4 |
FISH stratification (n = 298)* | ||
Low-risk | 211 | 70.8 |
Intermediate/high-risk | 87 | 29.2 |
Previous treatment | ||
Yes | 42 | 13.3 |
No | 274 | 86.7 |
Characteristic . | No. of patients (N = 316) . | % . |
---|---|---|
Median age, y | 66 (33-90) | |
Median LDH, U/L (range; n = 243) | 338 (136-1432) | — |
Median β2-microglobulin, mg/L (range; n = 294) | 2.2 (0.36-14.3) | — |
Sex | ||
Male | 177 | 56.0 |
Female | 139 | 44.0 |
Binet stage (n = 289) | ||
A | 242 | 83.7 |
B-C | 47 | 16.3 |
BM pattern (n = 149) | ||
Not diffuse | 125 | 83.9 |
Diffuse | 24 | 16.1 |
IGHV mutational status (n = 268) | ||
Mutated (≥ 2%) | 184 | 68.7 |
Unmutated (< 2%) | 84 | 31.3 |
CD38 (n = 308) | ||
CD38− (< 30%) | 233 | 75.6 |
CD38+ (≥ 30%) | 75 | 24.4 |
ZAP-70 (n = 264) | ||
ZAP-70− (< 20%) | 160 | 60.6 |
ZAP-70+ (≥ 20%) | 104 | 39.4 |
CD49d (n = 164) | ||
CD49d− (< 30%) | 106 | 64.6 |
CD49d+ (≥ 30%) | 58 | 35.4 |
FISH stratification (n = 298)* | ||
Low-risk | 211 | 70.8 |
Intermediate/high-risk | 87 | 29.2 |
Previous treatment | ||
Yes | 42 | 13.3 |
No | 274 | 86.7 |
LDH indicates lactate dehydrogenase; and —, not applicable.
Low-risk cytogenetic indicates no abnormalities or 13q−; Intermediate/high-risk cytogenetic, 11q−, 17p−, or trisomy 12.